https://orcid.org/0000-0002-1359-4982
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ying Cheng, James Chih-Hsin Yang, Isamu Okamoto, Li Zhang, Jie Hu, Donglin Wang, Chengping Hu, Jianying Zhou, Lin Wu, Lejie Cao, Jiwei Liu, Helong Zhang, Hong Sun, Ziping Wang, Hongjun Gao, Yan Yan, Suijun Xiao, Jianxin Lin, M. Catherine Pietanza & Takayasu Kurata. (2023) Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia. Immunotherapy 15:13, pages 1029-1044.
Read now
Read now
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu & Hongming Pan. (2022) Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors. Future Oncology 18:17, pages 2053-2062.
Read now
Read now
Yun Dai, Munawaer Muaibati, Weiming Xie, Abuduyilimu Abasi, Kexin Li, Qing Tong, Tao Zhang, Yifan Meng, Liang Zhuang & Xiaoyuan Huang. (2022) PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review. Cancer Investigation 40:3, pages 293-309.
Read now
Read now
Ching-Yi Chen, Wang-Chun Chen, Chao-Ming Hung & Yu-Feng Wei. (2021) Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis. Immunotherapy 13:14, pages 1165-1177.
Read now
Read now
Run-Cong Nie, Jin-Ling Duan, Yao Liang, Xiao-Jiang Chen, Yong-Ming Chen, Tian-Qi Luo, Guo-Ming Chen, Yun Wang & Yuan-Fang Li. (2020) Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy 12:18, pages 1313-1324.
Read now
Read now
Articles from other publishers (28)
Albert Q. Wu, David J. Benjamin, Vinay Prasad & Timothée Olivier. (2024) Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials. European Journal of Cancer 201, pages 113925.
Crossref
Crossref
Gonzalo Ruiz, Diego Enrico, Yamil D. Mahmoud, Alan Ruiz, María Florencia Cantarella, Laura Leguina, Mariana Barberis, Asunción Beña, Esteban Brest, Solange Starapoli, Andrea Mendoza Bertelli, Florencia Tsou, Carmen Pupareli, María Pía Coppola, Alejandra Scocimarro, Susana Sena, Patricio Levit, Aldo Perfetti, Enrique Aman, María Romina Girotti, Oscar Arrieta, Claudio Martín & Rubén Salanova. (2024)
Association of
PD‐L1
expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients
. Thoracic Cancer.
Crossref
Crossref
J. Ajani, F. El Hajbi, D. Cunningham, M. Alsina, P. Thuss-Patience, G.V. Scagliotti, M. Van den Eynde, S-B. Kim, K. Kato, L. Shen, L. Li, N. Ding, J. Shi, G. Barnes & E. Van Cutsem. (2024) Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open 9:1, pages 102202.
Crossref
Crossref
Liyuan Ke, Su Li & Danxue Huang. (2023) The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. International Immunopharmacology 124, pages 110986.
Crossref
Crossref
Nam P. Nguyen, Juliette Thariat, Olena Gorobets, Vincent Vinh-Hung, Lyndon Kim, Sergio Calleja Blanco, Maria Vasileiou, Meritxell Arenas, Thandeka Mazibuko, Huan Giap, Felix Vincent, Alexander Chi, Gokoulakrichenane Loganadane, Mohammad Mohammadianpanah, Agata Rembielak, Ulf Karlsson, Ahmed Ali, Satya Bose & Brandi R. Page. (2023) Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers 15:20, pages 4981.
Crossref
Crossref
Shang‐Hsuan Peng, Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu & Yen‐Shen Lu. (2023)
Disparity in survival benefits of pembrolizumab between Asian and
non‐Asian
patients with advanced cancers: A systematic review and
meta‐regression
analysis
. Cancer Medicine 12:19, pages 20035-20051.
Crossref
Crossref
Yichao Han, Si-Yang Maggie Liu, Runsen Jin, Wangyang Meng, Yi-Long Wu & Hecheng Li. (2023) A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer. Frontiers in Immunology 14.
Crossref
Crossref
Eleni Manthopoulou, Daryl Ramai, Jahnvi Dhar, Jayanta Samanta, Alexandros Ioannou, Ekaterina Lusina, Rodolfo Sacco & Antonio Facciorusso. (2023) Cholangiocarcinoma in the Era of Immunotherapy. Vaccines 11:6, pages 1062.
Crossref
Crossref
Esraa Al-Khateeb, Manal A. Abbas, Majd B. Khader & Maher A. Sughayer. (2023) Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis. The International Journal of Biological Markers 38:1, pages 53-60.
Crossref
Crossref
Satya Das, Sharon Phillips, Cody L. Lee, Rajiv Agarwal, Emily Bergsland, Jonathan Strosberg, Jennifer A. Chan, Heather LaFerriere, Robert A. Ramirez, Jordan Berlin & Arvind Dasari. (2023) Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours – A systematic review and meta-analysis. European Journal of Cancer 182, pages 43-52.
Crossref
Crossref
Tianshu Liu, Yuxian Bai, Xiaoyan Lin, Wei Li, Jufeng Wang, Xiaochun Zhang, Hongming Pan, Chunmei Bai, Li Bai, Ying Cheng, Jingdong Zhang, Haijun Zhong, Yi Ba, Wenwei Hu, Ruihua Xu, Weijian Guo, Shukui Qin, Nong Yang, Jianwei Lu, Kohei Shitara, Ming Lei, Mingshun Li, Nicole Bao, Tian Chen & Lin Shen. (2022)
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma:
CheckMate
649 Chinese subgroup analysis
. International Journal of Cancer 152:4, pages 749-760.
Crossref
Crossref
Shun Lu, Jian Fang, Ziping Wang, Yun Fan, Yunpeng Liu, Jianxing He, Jianying Zhou, Jie Hu, Jinjing Xia, Wenxin Liu, Jane Shi, Jing Yi & Lejie Cao. (2022) Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer. Cancer Medicine 12:3, pages 2666-2676.
Crossref
Crossref
Gong-Kai Huang, Chao-Cheng Huang, Chih-Hsiung Kang, Yuan-Tso Cheng, Po-Ching Tsai, Ying-Hsien Kao & Yueh-Hua Chung. (2023) Genetic Interference of FGFR3 Impedes Invasion of Upper Tract Urothelial Carcinoma Cells by Alleviating RAS/MAPK Signal Activity. International Journal of Molecular Sciences 24:2, pages 1776.
Crossref
Crossref
Minyoung Lee, Kyeongseob Jeong, Yu Rang Park & Yumie Rhee. (2023) Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database. Metabolism 138, pages 155311.
Crossref
Crossref
Hirotsugu Kenmotsu, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Morihito Okada, Toyofumi Fengshi Chen‐Yoshikawa, Yuichiro Ohe, Wataru Nishio, Shizuka Nakagawa & Haruka Nagao. (2022)
Adjuvant atezolizumab in Japanese patients with resected stage
IB‐IIIA
non‐small cell lung cancer (
IMpower010
)
. Cancer Science 113:12, pages 4327-4338.
Crossref
Crossref
Shuhei Takahashi, Shintaro Narita, Nobuhiro Fujiyama, Shingo Hatakeyama, Takashi Kobayashi, Renpei Kato, Sei Naito, Toru Sakatani, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, Taketoshi Nara, Souhei Kanda, Kazuyuki Numakura, Mitsuru Saito, Wataru Obara, Norihiko Tsuchiya, Chikara Ohyama, Osamu Ogawa & Tomonori Habuchi. (2022) Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. Cancer Science 113:12, pages 4059-4069.
Crossref
Crossref
Dae Won Kim, Young-chul Kim, Bence P. Kovari, Vincent Chung, Olatunji B. Alese, Bassel F. El-Rayes, Daneng Li, Wungki Park & Richard D. Kim. (2022) Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. European Journal of Cancer 176, pages 171-180.
Crossref
Crossref
Kaili Yang, Jiarui Li, Lin Zhao, Zhao Sun & Chunmei Bai. (2022) Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors. Frontiers of Medicine 16:5, pages 773-783.
Crossref
Crossref
Lauren Fane, Tithi Biswas, Charulata Jindal, Yuk Ming Choi & Jimmy T. Efird. (2022) Breast Cancer Disparities in Asian Women: The Need for Disaggregated Research. International Journal of Environmental Research and Public Health 19:16, pages 9790.
Crossref
Crossref
Vinicius Knackfuss Gonçalves, Fernando Sabino Marques Monteiro, Antonia Angeli Gazola, Felipe Pizzolo, Júlia Elisa Hübner, Rodrigo Pellegrini, Alessandra Borba & André P. Fay. (2022) Geographical Differences in Kidney Cancer Outcomes of Patients Treated with Immunotherapy: A Systematic Review. Kidney Cancer 6:2, pages 129-136.
Crossref
Crossref
Zi-Chun Li, Yu-Ting Sun, Ming-Yu Lai, Yi-Xin Zhou & Miao-Zhen Qiu. (2022) Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. International Immunopharmacology 109, pages 108790.
Crossref
Crossref
C. S. Pramesh, Rajendra A. Badwe, Nirmala Bhoo-Pathy, Christopher M. Booth, Girish Chinnaswamy, Anna J. Dare, Victor Piana de Andrade, David J. Hunter, Satish Gopal, Mary Gospodarowicz, Sanjeeva Gunasekera, Andre Ilbawi, Sharon Kapambwe, Peter Kingham, Tezer Kutluk, Nirmal Lamichhane, Miriam Mutebi, Jackson Orem, Groesbeck Parham, Priya Ranganathan, Manju Sengar, Richard Sullivan, Soumya Swaminathan, Ian F. Tannock, Vivek Tomar, Verna Vanderpuye, Cherian Varghese & Elisabete Weiderpass. (2022) Priorities for cancer research in low- and middle-income countries: a global perspective. Nature Medicine 28:4, pages 649-657.
Crossref
Crossref
Moh. Ramadhani Soeroso, Noni Novisari Soeroso, Setia Putra Tarigan & Elisna Syahruddin. (2022) Adverse Event Profiles of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adenocarcinoma Lung Patients in North Sumatera Population. Open Access Macedonian Journal of Medical Sciences 10:T7, pages 134-137.
Crossref
Crossref
Meshach Asare-Werehene, Hideaki Tsuyoshi, Huilin Zhang, Reza Salehi, Chia-Yu Chang, Euridice Carmona, Clifford L. Librach, Anne-Marie Mes-Masson, Chia-Ching Chang, Dylan Burger, Yoshio Yoshida & Benjamin K. Tsang. (2022) Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes. Cancers 14:4, pages 1039.
Crossref
Crossref
Konstantinos Kamposioras, Panagiotis Ntellas, Michail Nikolaou, Theodora Germetaki, Ioanna Gazouli, Katerina Dadouli, George Zarkavelis, Anna-Lea Amylidi, Maria Tolia & Davide Mauri. (2021) Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. JNCI Cancer Spectrum 5:6.
Crossref
Crossref
Yong-Liang Yang, Zhi-Qiang Li, Qiu-Lu Wang, Jing-Jing Gu, Xin-Jian Fang & Guan-Hong Huang. (2021) Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review. Clinical Therapeutics 43:11, pages 1997-2012.
Crossref
Crossref
Yi-Xin Zhou, Ping Chen, Yu-Ting Sun, Bei Zhang & Miao-Zhen Qiu. (2021) Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting. Frontiers in Oncology 11.
Crossref
Crossref
Raymond U. Osarogiagbon, Helmneh M. Sineshaw, Joseph M. Unger, Ana Acuña-Villaorduña & Sanjay Goel. (2021) Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. American Society of Clinical Oncology Educational Book:41, pages 66-78.
Crossref
Crossref